<DOC>
	<DOCNO>NCT01259934</DOCNO>
	<brief_summary>The aim study evaluate effect give adjuvant treatment intermediate dos interferon-alpha2b patient operate high risk melanoma . Patients randomly assign either observation interferon treatment 2 different duration . The outcome respect overall survival , relapse-free survival , side effect quality life analyse .</brief_summary>
	<brief_title>Nordic Adjuvant IFN Melanoma Trial</brief_title>
	<detailed_description>This open multicenter , prospective randomise phase III trial evaluate efficacy two different schedule Interferon-alpha2b ( IFN-alpha2b ) administer adjuvant set adequate surgery high risk cutaneous melanoma patient ( T4N0M0/TxN1-2M0 ) . The patient operate either thick primary melanoma ( &gt; 4 mm ) without evidence distant metastasis undergone surgery regional lymph node metastasis . The study consist control arm ( A ) two treatment arm , B C. The outcome arm B C adjuvant treatment IFN-alpha2b compare outcome arm A patient observed surgery . The primary endpoint overall survival . Secondary endpoint relapse-free survival , safety-toxicity health-related quality life .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>T4 N0 M0 Thick primary melanoma : &gt; 4.0 mm Breslow depth , without lymph node involvement , Tx N12 M0 Primary melanoma thickness regional lymph node metastasis confirm lymphadenectomy , Tx N12 M0 Recurrent melanoma regional lymph node ( ) confirm lymphadenectomy . ECOG performance status 01 No active medical psychiatric disorder require therapy would prevent completion protocol Written inform consent Patients unknown primary site melanoma primary melanoma originate apart skin , except subungual melanoma Patients clinical , radiological/laboratory pathological evidence incompletely resect melanoma distant metastatic disease Patients prior adjuvant radiotherapy , chemotherapy , immunotherapy include preoperative infusion perfusion therapy Female patient pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Randomized Phase III trial</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Interferon</keyword>
	<keyword>Melanoma</keyword>
</DOC>